Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| UAB | Other Identifier | UAB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders
Background
Over the last decade, major advances have occurred in histiocytic disorders with the discovery of MAPK-ERK pathway mutations leading to targeted therapeutics using BRAF- and MEK-inhibitors. However, there is a lack of large studies informing the burden of morbidity and mortality among people with histiocytosis. Institutional studies in pediatric LCH suggest that survivors suffer from long-term impairment of health related quality of life, cognitive dysfunction, pituitary dysfunction, and hearing difficulties in 20-50% cases. Studies from the investigative team and others have also shown a high incidence of acute myeloid leukemia and other second primary malignancies in pediatric and adult LCH. Chronic medical conditions may arise as a function of the disease biology or due to cancer therapy, as seen in other hematologic malignancies.
Design
Retrospective cohort study aimed at determining the risk of chronic health conditions and cause-specific mortality in pediatric and adult patients with histiocytic disorders. The study will include patients from the Histiocytosis Association registry and other institutions including UAB (n~6000). The participants will complete a validated questionnaire capturing details of chronic health conditions, health related quality of life, cognitive/psychological function, and healthcare utilization.
Future directions
The results from our study will be instrumental in formulating follow-up guidelines for histiocytic disorders and developing targeted survivorship programs to improve overall outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Chronic health conditions diagnosed after LCH diagnosis graded using the Common Terminology Criteria for Adverse Events (CTCAE), v5.0 (https://ctep.cancer.gov) | The CTCAE criteria for CHCs distinguishes each acute and chronic condition (including SPMs) in persons with cancer from grades 1 through 4 with unique clinical descriptions of severity (grade 1, mild; grade 2, moderate; grade 3, severe; grade 4, life-threatening/disabling). The main outcome will be the number of distinct CTCAE grade 3-4 conditions among LCH cases compared with unaffected (non-cancer) controls. | From diagnosis of histiocytic disorder to age at completion of survey, assessed up to 200 months |
| All-cause and cause-specific mortality | Causes of death will be grouped into primary cancer (LCH)-related mortality (PCRM) and non-primary cancer-related mortality (NPCRM - death from all causes other than the index LCH diagnosis) by two independent investigators. | 2 years preceding death |
| Measure | Description | Time Frame |
|---|---|---|
| Factors associated with new-onset morbidity | We will build a prediction model that has a good discrimination for predicting CHC, SPMs, and psychological outcomes separately using data from the LCH (case) cohort. | From diagnosis to age at completion of survey, assessed up to 200 months |
Not provided
Inclusion Criteria:
diagnosis of histiocytic disorder at any age
Exclusion Criteria:
Not provided
Not provided
Individuals with diagnosis of histiocytic disorder are eligible to participate, including family members (next of kin) of deceased individuals.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gaurav Goyal, MD | Contact | 1-866-438-1640 | histio@uabmc.edu |
| Name | Affiliation | Role |
|---|---|---|
| Gaurav Goyal, MD | University of Alabama at Birmingham | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alabama at Birmingham | Recruiting | Birmingham | Alabama | 35233 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015614 | Histiocytosis |
| D006646 | Histiocytosis, Langerhans-Cell |
| D031249 | Erdheim-Chester Disease |
| D015618 | Histiocytosis, Sinus |
| D054747 | Histiocytic Sarcoma |
| D016609 | Neoplasms, Second Primary |
| ID | Term |
|---|---|
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D017563 | Lung Diseases, Interstitial |
| D008171 | Lung Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D012140 | Respiratory Tract Diseases |
| D015616 | Histiocytosis, Non-Langerhans-Cell |
| D015620 | Histiocytic Disorders, Malignant |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |